- About UsOpenClose
- LeadershipOpenClose
- BoardOpenClose
- TechnologyOpenClose
- PublicationsOpenClose
- PipelineOpenClose
- For PatientsOpenClose
- For InvestorsOpenClose
- NewsroomOpenClose
- Media CoverageOpenClose
- Press ReleasesOpenClose
| Current Portfolio | Discovery | Preclinical | Phase 1 |
|---|---|---|---|
CT – 1119 (CAR-Monocyte)Discovery | Preclinical | Phase 1 |
|||
In Vivo CAR-Macrophage: GPC3+ Solid TumorsDiscovery | Preclinical | Phase 1 |
|||
In Vivo CAR-Macrophage: Oncology TargetsDiscovery | Preclinical | Phase 1 |
|||
CT-2401 (Liver Fibrosis)Discovery | Preclinical | Phase 1 |
|||
Autoimmune DiseaseDiscovery | Preclinical | Phase 1 |
CT-1119 is an ex vivo gene-modified autologous CAR-Monocyte cellular therapy to target mesothelin-positive solid tumors.
Carisma is partnering with Moderna Therapeutics to develop the next generation of macrophage-targeted in vivo therapies to address multiple cancer targets. The lead program is an anti-glypican 3 (GPC3) in vivo CAR-M therapy for the treatment of hepatocellular carcinoma (HCC).
Carisma is partnering with Moderna Therapeutics to develop the next generation of macrophage-targeted in vivo therapies to address multiple cancer targets. Five targets have been nominated (including the lead), with the option to identify an additional 7 oncology targets.
CT-2401 leverages TIM4 mRNA-loaded Kupffer cell tropic LNPs to restore TIM4 expression, repairing efferocytosis and dramatically reducing fibrosis.
In collaboration with Moderna, Carisma has two in vivo CAR-M research programs for the treatment of autoimmune diseases associated with two distinct targets where there is significant unmet medical need.
Carisma’s scientists are expanding the functionality of engineered macrophages to increase the number of patients that can potentially benefit from this transformative technology. With research programs targeting liver fibrosis, neurodegeneration and autoimmune disorders, Carisma is pushing the boundaries of what is possible.
We are actively seeking partnerships for the development of complementary therapeutic approaches to explore a broader set of indications and reach more patients.
| R & D Engine | Discovery | Preclinical | Phase 1 |
|---|---|---|---|
Autoimmune diseasesDiscovery | Preclinical | Phase 1 |
If there are important updates to our pipeline or research, you can be the first to hear about them.
Read the latest news, announcements, and more in the Carisma newsroom.
Press Releases Media CoverageWe have decades of experience in the industry, and are working to a develop a new approach to cell therapies.
Get to know the team committed to developing innovative treatments for patients.
Our Team